

***Fiscal Year 2015/2016 Vision Research Program (VRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Technology/Therapeutic Development Award Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-15-VRP-TTDA</p>	<p>Must be an independent investigator at any level.</p>	<ul style="list-style-type: none"> • Supports the translation of promising preclinical findings into products for clinical applications, including detection, diagnosis, treatment or quality of life. • At the end of this period of performance this work should be sufficient to support an IDE, IND or continue to clinical trials (where applicable). • The product(s) to be developed may be a tangible item such as a pharmacologic agent or device, or a knowledge based product such as clinical guidance for standard of care. • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding (direct and indirect costs) for the entire period of performance will not exceed \$1,500,000. • Indirect costs are to be budgeted in accordance with the organization's negotiated rate. 	<p>Pre-application (Letter of Intent): December 2, 2015 5:00 p.m. ET</p> <p>Application: December 16, 2015 11:59 p.m. ET</p>
<p>Clinical Trial Award Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-15-VRP-CTA</p>	<p>Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports research with the potential to have a major impact on the treatment or management of visual injury and/or dysfunction. • Must support a clinical trial and should not be used for preclinical research studies. • At the end of this period of performance this work should show clear progress toward the next stage of implementation (i.e., Phase II clinical trials, FDA clearance for a medical device, etc.). 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding (direct and indirect costs) for the entire period of performance will not exceed \$3,000,000. • Indirect costs are to be budgeted in accordance with the organization's negotiated rate. 	<p>Pre-application (Letter of Intent): December 2, 2015 5:00 p.m. ET</p> <p>Application: December 16, 2015 11:59 p.m. ET</p>